



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE MEETING HELD ON WEDNESDAY 19th APRIL 2017 AT
12.30pm

IN SEMINAR ROOM 6, LEARNING & DEVELOPMENT CENTRE,
ROYAL BLACKBURN HOSPITAL

PRESENT:

Dr D Gavan (DG)	Consultant Radiologist ELHT (Chairperson)
Dr L Rogan (LR)	Head of Medicines Commissioning NHS EL CCG
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Dr S Preeti (SP)	GP, BwD CCG

In Attendance

Ms L Prince	Medicines Management Technician EL CCG
-------------	--

2017/056: APOLOGIES:

Dr K Burch (KB)	Consultant Microbiologist ELHT
Dr S Davies (SD)	GP, EL CCG
Mrs L Holden (LH)	Pharmacist LCFT (representing Ms S Ramdour)
Dr T McKenzie (TM)	GP, EL CCG

2017/057: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2017/058: MINUTES OF FEBRUARY MEETING:

Amend 2017/044 Pregabalin Axalid[®] to licence for neuropathic pain pending.
Accepted as a correct record.

2017/059: MATTERS ARISING:

2017/007: Formulary Updates – Sodium valproate – NF not been able to contact Gareth Price. A new Patient Safety alert has been published by NHS Improvements with an October deadline for actions to be completed. It has been also flagged at LMMG and is being pursued with LTHT.

2017/020: LMMG Recommendations (from Jan) Vitamin D Position Statement – new LMMG position statement due and then products to be reviewed.

2017/041: Tolvaptan/Demeclocycline for Hyponatraemia – endocrinology have been asked to review appropriateness and place in therapy given European guidelines do not recommend.

2017/060: NEW PRODUCT REQUEST – PILOCARPINE TABLETS

Pilocarpine tablets are requested by Head & Neck directorate for radiation-induced xerostomia and Sjogren's syndrome. The request was approved for second line management when first line topical agents have not been effective.

Resolved: Pilocarpine tablets to be included on formulary. Traffic Light: Amber

2017/061: LMMG CONSULTATIONS (for May LMMG)

Psoriasis Primary Care Guideline

The guideline has products included which do not reflect the health economy joint formulary. On page 4 the box in the middle requires advice of specialist but appears before the referral to specialist services. JV will discuss products with integrated dermatology service with a view to amending any guidance issued.

Blood Glucose Testing Guidance

EL CCG has already sent comments to LMMG. They would prefer to keep ELHE existing guidance which reflects NICE. Comments from ELHT diabetologists concerning quantities, other medication to include and up to date DVLA advice to be sent to LMMG.

Feraccru Recommendation

ELMMB supports the black recommendation.

Resolved: CW to send responses to LMMG.

2017/062: LMMG RECOMMENDATIONS (from March)

Guidelines for Prescribing Nutritional Supplements Post Bariatric Surgery.

Concern was expressed that some were amber and some black depending on the indication. It was agreed that all would have a black traffic light in ELHE. LMMG to be informed of this decision.

Eflornithine Recommendation

The recommendation was agreed as written for ELHE.

Traffic Light: Black

2017/063: FORMULARY UPDATES

Unlicensed Specials – defer. To be brought back to a later meeting.

2017/064: ELHT INTRAVENOUS FLUID GUIDELINES FOR CHILDREN

The IV fluid guidelines for children have been developed and approved in the paediatric directorate. Approved by ELMMB

Resolved: ELMMB approved IV Fluid Guidelines for Children.

2017/065: NICE RECOMMENDATIONS (from March)

Elotuzumab for previously treated multiple myeloma (terminated appraisal) (TAG 434)

Traffic Light: BLACK

Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) (TAG 435)

Traffic Light: BLACK

Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) (TAG 436)

Traffic Light: BLACK

Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) (TAG 437)

Traffic Light: BLACK

Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) (TAG 438)

Traffic Light: BLACK

Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TAG 439) recommended as an option by NICE. Approved in line with NICE. NHS England commissioned.

Traffic Light: RED

Ustekinumab for treating active psoriatic arthritis (TAG 340) is recommended as an option by NICE. Approved in line with NICE. CCG commissioned.

Traffic Light: RED

Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) (TAG 240 updated March 17)

Traffic Light: BLACK

Ustekinumab for the treatment of adults with moderate to severe psoriasis (TAG 180 updated March 17) is recommended as an option by NICE. Approved in line with NICE. CCG commissioned.

Traffic Light: RED

STANDING ITEMS

2017/066: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – March 2017

Minutes acknowledged

2017/067: FOR ACTION/INFORMATION: LANCASHIRE CARE FOUNDATION TRUST D&T MINUTES – March 2017

Minutes acknowledged

DATE OF NEXT MEETING – Next meeting is **Wednesday 17th May 2017 12.30pm**, Seminar Room 8, Learning and Development Centre, RBH.

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 19TH APRIL 2017

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2017/007	Formulary Updates – Sodium valproate – ask LCFT to consider all patients to be referred back. LMMG pursuing with LTHT	LH LR	Apr 17 Apr 17
2017/041	Tolvaptan/Demeclocycline for Hyponatraemia – endocrinologist to be asked to review	VG	May 17
2017/061:	LMMG Consultations: Psoriasis Primary Care Guideline – To review products in line with formulary and discuss with Integrated Dermatology Service.	JV	May 17